What is Immusoft?
Based in Seattle, Washington, Immusoft Corporation is a pioneer in the field of synthetic biology, specifically focusing on Immune System Programming. The company's core technology platform is designed to modify a patient's own B cells, effectively transforming them into biological factories that produce gene-encoded medicines. This approach represents a paradigm shift in how chronic and serious diseases are treated, moving away from traditional pharmaceutical interventions toward personalized, cell-based therapies.
By utilizing the body's own immune system as a delivery vehicle, Immusoft aims to provide long-term, sustainable therapeutic effects. The company's market position is defined by its intellectual property in cellular engineering and its ability to navigate the complex regulatory environment associated with gene therapy. As the biotech industry increasingly pivots toward precision medicine, Immusoft stands at the intersection of immunology and genetic engineering, positioning itself as a key player in the next generation of healthcare innovation.
How much funding has Immusoft raised?
Immusoft has raised a total of $33.3M across 5 funding rounds:
Private Equity
$2.4M
Series A
$2.7M
Series B
$20M
Debt
$150K
Other Financing Round
$8M
Private Equity (2014): $2.4M, investors not publicly disclosed
Series A (2016): $2.7M, investors not publicly disclosed
Series B (2019): $20M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Other Financing Round (2023): $8M backed by The California Institute for Regenerative Medicine
Key Investors in Immusoft
The California Institute for Regenerative Medicine
CIRM is a state agency dedicated to accelerating stem cell and gene therapy research to deliver transformative treatments for serious diseases. The organization provides critical funding and infrastructure support to bridge the gap between early-stage discovery and clinical-stage development.
PPP
Public-Private Partnership
Undisclosed Investor
An undisclosed institutional backer that has participated in the company's historical funding rounds, contributing to the overall capital structure and long-term growth strategy.
What's next for Immusoft?
With the recent strategic investment, Immusoft is well-positioned to accelerate its clinical development programs and expand its research infrastructure. The focus will likely shift toward optimizing the scalability of its B-cell programming platform, ensuring that these complex therapies can be manufactured efficiently for broader patient populations. Furthermore, the company is expected to leverage this capital to strengthen its intellectual property portfolio and pursue strategic partnerships that can facilitate the commercialization of its lead candidates.
As the firm moves into its next phase of growth, the emphasis will remain on demonstrating clinical efficacy and safety in human trials. The support from specialized regenerative medicine agencies highlights the high-impact potential of Immusoft's technology, suggesting a future where the company could fundamentally alter the standard of care for patients suffering from previously intractable conditions.
